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BRIEF REPORT: PREVENTION RESEARCH
Medication Sharing Is Rare Among African HIV-1
Serodiscordant Couples Enrolled in an Efficacy Trial of Oral
Pre-exposure Prophylaxis (PrEP) for HIV-1 Prevention
Kerry A. Thomson, MPH,* Jessica E. Haberer, MD, MS,† Mark A. Marzinke, PhD,‡
Andrew Mujugira, MBChB, PhD, MSc,§ Craig W. Hendrix, MD,k Connie Celum, MD, MPH,¶
Patrick Ndase, MBChB, MPH,# Allan Ronald, MD,** David R. Bangsberg, MD, MPH,†† and
Jared M. Baeten, MD, PhD,‡‡ for the Partners PrEP Study Team
Abstract: Sharing of pre-exposure prophylaxis (PrEP) medications
is a concern for PrEP implementation. For HIV-1 serodiscordant
couples, sharing may undermine the HIV-1 prevention benefit and
also cause antiretroviral resistance if taken by HIV-1 infected
partners. Within a PrEP efficacy trial among HIV-1 serodiscordant
couples, we assessed the occurrence of PrEP sharing by self-report
and plasma tenofovir concentrations in HIV-1 infected partners.
PrEP sharing was self-reported at,0.01% of visits, and 0%–1.6% of
randomly selected and 0% of purposively selected specimens from
HIV-1 infected participants had detectable tenofovir concentrations
(median: 66.5 ng/mL, range: 1.3–292 ng/mL). PrEP sharing within
HIV-1 serodiscordant couples was extremely rare.
Key Words: HIV-1, pre-exposure prophylaxis, HIV-1 serodiscord-
ant couples, adherence, prescription drug diversion
(J Acquir Immune Defic Syndr 2017;75:184–189)
INTRODUCTION
Pre-exposure prophylaxis (PrEP), in which an HIV-1
uninfected individual takes oral antiretrovirals to prevent
HIV-1 acquisition, is recommended by the World Health
Organization for populations at high risk of HIV-1, including
HIV-1 serodiscorant couples.1 Open-label studies of PrEP are
ongoing, and have shown high adherence and reductions in
HIV-1 acquisition of 90% or more.2–6
“Drug diversion,” where HIV-1 uninfected individuals
share or sell their prescribed PrEP medications, is a potential
challenge for PrEP implementation.7–9 To sufficiently disrupt
HIV-1 replication, antiretroviral therapy (ART) for HIV
infected adults should include at least 3 drugs from 2 classes
of HIV antiretrovirals.10 Use of mono or dual agent
antiretrovirals prescribed as PrEP by HIV-1 infected persons
could result in antiretroviral resistance due to suboptimal viral
suppression and undermine the level of protection for the
intended HIV-1 uninfected user due to insufficient drug
concentrations.11 PrEP sharing may occur more frequently
by HIV-1 uninfected persons with a known HIV-1 infected
partner, particularly if their partner is not yet eligible for or
experiences barriers accessing ART for their own treatment.
We assessed the extent to which PrEP sharing occurred
within a large cohort of HIV-1 serodiscordant couples
enrolled in an efficacy trial in Africa.
METHODS
Study Population
The Partners PrEP Study was a phase III, randomized,
double-blind, placebo-controlled, 3-arm clinical trial of daily
oral PrEP (ClinicalTrials.gov NCT00557245). Beginning in
2008, the HIV-1 uninfected partner in 4747 HIV-1 serodis-
cordant couples was randomized to receive once-daily
tenofovir (TDF), combination tenofovir–emtricitabine (TDF/
FTC), or matching placebo and followed for a maximum of
48 months for safety and HIV-1 seroconversion. The Partners
PrEP Study was conducted at 9 clinical research sites in
Kenya and Uganda; study details have been described
previously.12–14 In July 2011, the Data and Safety Monitoring
Board recommended discontinuation of the placebo arm due
to the demonstrated 67% efficacy for HIV-1 prevention with
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TDF and 75% efficacy with TDF/FTC.13 Participants were
offered the option to continue in the study and receive open-
label PrEP, with participants in the placebo arm re-randomized
to TDF or TDF/FTC.
Study Procedures
This analysis includes data from the duration of study
follow-up (2008–2013). HIV-1 uninfected participants
attended monthly study visits. At each visit, participants were
counselled on the importance of adherence to study drug and
the potential danger of HIV-1 infected partners taking study
drug.13,15 Plasma from HIV-1 uninfected partners was
collected at enrollment, months 1, 3, and quarterly thereafter,
and study exit. At enrollment, all HIV-1 infected partners
were ineligible for ART based on national guidelines and self-
reported not taking ART. HIV-1 infected participants
attended quarterly study visits and were referred to initiate
ART once they met national eligibility criteria. Plasma from
HIV-1 infected participants was collected at enrollment, at 6
months intervals thereafter, and study exit. Plasma was also
collected at any visit where an HIV-1 uninfected participant
first tested positive for HIV, and as soon as possible from
their study partner. Self-reported data on sharing study drug,
including the number of tablets shared, were obtained from
HIV-1 uninfected partners at monthly study visits, re-
randomization, study exit, and annually from HIV-1
infected partners.
Assessment of PrEP Medication Sharing
For the current analysis, we assessed PrEP medication
sharing using self-report and objective assessment through
plasma tenofovir testing in 4 different groups that were
selected based on potential or previously documented non-
adherence to study drug (Fig. 1). Tenofovir concentrations in
plasma were measured using previously described validated
liquid chromatography-mass spectrometry/mass spectrometry
methods.16,17 Detectable tenofovir for all analyses was
defined as $0.31 ng/mL; this threshold was the lower limit
of quantification and has 92% specificity for at least one
dose in the past week.17 Results from 2 prior analyses13,18
informed the sampling scheme for the current study, and
additional testing of plasma from HIV-1 infected subjects
was performed. The Ancillary Adherence Study (AAS)
assessed use of study drug during the blinded phase of the
trial at 3 sites in Uganda.15 In this substudy, plasma was
collected from both HIV-1 uninfected and HIV-1 infected
members of 1147 couples at unannounced home visits
during follow-up. Group 1 was a random sample of plasma
specimens collected at AAS unannounced home visits
from HIV-1 infected participants (n = 100), with the
rationale that participants sharing medication may modify
this behavior before clinic visits and thus an unannounced
visit would be the best opportunity to identify sharing.
Group 2 included specimens belonging to HIV-1 infected
participants enrolled in the AAS whose HIV-1 uninfected
study partner’s specimen was included in a previous
analysis testing 268 randomly selected home specimens
and did not have detectable tenofovir concentrations (n =
29).18 Group 3 was derived from a case-cohort study of
plasma tenofovir concentrations nested within the Partners
PrEP Study, including 298 randomly-selected HIV-1
uninfected participants from the active arms, which
assessed the association between PrEP use and HIV-1
protection.13 Group 3 included specimens belonging to
HIV-1 infected participants whose HIV-1 uninfected study
partner’s specimen did not have detectable tenofovir con-
centrations among the 1802 randomly selected specimens in
the cohort analysis (n = 406).12,13 The rationale for both
Groups 2 and 3 was that the absence of tenofovir in the HIV-1
uninfected partner may have been because PrEP medication
was shared with the HIV-1 infected partner. Group 4 included
HIV-1 infected participants whose study partner acquired
HIV-1 during study follow-up (n = 52), with the rationale that
these participants were not taking sufficient PrEP to achieve
FIGURE 1. Assessment of potential sharing of PrEP medication within HIV-1 serodiscordant couples, frequency, (%), [95% CI].
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the HIV-1 prevention benefit and may have diverted PrEP to
their partner.
The underlying sampling scheme for Groups 1, 2, and 3
was a random selection across the study population; within
Groups 2 and 3, and for Group 4, purposeful testing was done
to investigate drug sharing because uninfected partners had
no tenofovir concentrations in plasma and/or acquired HIV-1
during follow-up, despite having access to active study drug.
Specimens from couples who had been randomized to the
trial’s active arms and time periods when PrEP was dispensed
(ie, excluding study drug holds or missed visits) and ART
was not reported by the HIV-1 infected partner were eligible
for testing. We tested the specimen from the HIV-1 infected
participant that was closest to the date of undetectable
tenofovir concentrations (or HIV-1 seroconversion) in their
HIV-uninfected partner. For any HIV-1 infected participant
with detectable tenofovir concentrations we also tested the
following: an additional specimen from the same visit to rule
out inadvertent specimen mix-up, plasma archived at
enrollment/randomization (to assess undisclosed ART use),
plasma HIV-1 RNA viral load (undetectable defined as ,80
copies/mL), and plasma for emtricitabine.
Statistical Methods
We used SAS 9.4 (SAS Institute, Cary, NC) for
descriptive analysis; 95% confidence intervals were generated
with Stata 13.1 (StataCorp, College Station, TX), and one-
sided exact 95% confidence intervals were generated for
proportions in which the numerator was zero.
Ethics
The protocols for the parent study and AAS sub-study
were approved by ethics review committees at the University
of Washington and each study site. All participants provided
written informed consent.
RESULTS
Self-Report of Medication Sharing
Eight instances of HIV-1 infected partners using study
medication were self-reported from 7 couples across 155,875
study visits (8/155,875, ,0.01%). Five of these instances
were reported during follow-up and 3 were reported at study
exit, including one partner who reported medication sharing
once during follow-up and again at study exit (Fig. 1). No
seroconverter reported that their study partner had used their
study medication. All self-reported instances of HIV-1
infected participants taking study medication were described
as a small number of pills (maximum 4) during a single study
month, and there was no increase in reported drug sharing
once the placebo arm was discontinued.
Plasma Drug Concentrations
Of 290 specimens tested for this analysis, a total of 11
specimens from HIV-1 infected participants had detectable
tenofovir concentrations, though only 3 specimens are
potential instances of drug sharing (Fig. 1). These 11 speci-
mens came from 9 participants, none of whom self-reported
drug sharing, and all were investigated further for potential
drug sharing and undisclosed ART use (Table 1). Two of the
100 specimens in Group 1 had detectable tenofovir concen-
trations. Follow-up testing determined that Case 1 had
a tenofovir concentration of 71.5 ng/mL and an undetectable
HIV-1 viral load at enrollment, suggesting unreported
tenofovir-containing ART use before randomization and not
drug sharing thereafter. Case 2 had undetectable viral load
and a very low tenofovir concentrations at month 11 (1.3 ng/
mL), but no tenofovir present at enrollment. Thus, PrEP
sharing may have occurred in this case and overall, potential
drug sharing in Group 1 was 1.0%. In Group 2, 2 specimens
from the same participant had detectable tenofovir concen-
trations (Case 3). This couple was randomized to the TDF
arm; however, the HIV-1 infected partner had both tenofovir
and emtricitabine detected in a specimen collected at
enrollment. Case 3 is suggestive of undisclosed ART use
before study entry and unlikely PrEP sharing thereafter;
therefore potential drug sharing in Group 2 was 0%. In Group
3, 7 specimens from 6 participants had detectable tenofovir
concentrations (Cases 4–9). Three participants randomized to
the TDF/FTC arm had detectable tenofovir without emtrici-
tabine (Case 4–6) and Case 7 had detectable tenofovir before
randomization, all circumstances suggesting undisclosed
ART use. Case 8 had detectable tenofovir concentrations at
month 24 of follow-up and drug concentrations persisted until
study exit at month 36, and Case 9 had detectable tenofovir
concentrations and undetectable HIV-1 viral load at month
33. In the absence of detectable tenofovir concentrations at
randomization for these 2 cases, potential drug sharing in
Group 3 was 1.6%. No specimens in Group 4 had detectable
tenofovir and therefore potential drug sharing in this group
was 0%.
DISCUSSION
We found strong evidence that PrEP medication sharing
was extremely infrequent among East African HIV-1 sero-
discordant couples enrolled in a PrEP efficacy trial. No
extended drug sharing was self-reported, and random testing
and purposive sampling among groups most likely to share
study drug identified only 3 couples with evidence of
potential sharing of PrEP. Only one prior study has explored
drug sharing within the context of a PrEP efficacy trial and
also found that it was rare. Among a subset of HIV-1
uninfected women enrolled in the FEM-PrEP study, 10/224
(4%) of women reported that they gave their study pills to
someone else and described instances of selling or sharing
study medication to HIV-1 infected and uninfected individ-
uals.20 While outside the scope of the current analysis,
sharing PrEP with other HIV-1 uninfected individuals who
are not receiving adherence counselling and frequent HIV-1
testing is also a concern for PrEP delivery and should be
explored in future studies.
For 6 HIV-1 infected partners, we found detectable
drug at a time point prior to their study partner receiving PrEP
and/or concentrations that were not consistent with the arm to
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which the study couple had been randomized. Although it
was not feasible to test these specimens for all possible
antiretrovirals, the timing detectable tenofovir or emtricita-
bine strongly suggests undisclosed ART use. This finding is
consistent with prior studies that have described undisclosed
ART use occurring among 2.8%–5% of HIV-1 infected
partners participating in clinical trials of HIV-1 serodiscord-
ant couples.21,22 Undisclosed ART use could also explain the














1 1 Male 36 TDF/FTC Month 0: FTC ND, TFV 71.5.
Month 12: FTC NT, TFV
79.2. Month 15: FTC NT,
TFV 72.7.†
Month 0: UD. Month 12: UD. Detectable TFV only and no
FTC at randomization,
indicates drug could not
come from study partner.
Undisclosed ART at
enrollment
2 1 Male 36 TDF Month 0: FTC ND, TFV ND.
Month 11: FTC NT, TFV
1.32.†




may be ART initiation
without reporting to the
study team
3 2 Female 36 TDF Month 0: FTC 73.1, TFV
27.4. Month 6: FTC ND,
TFV 56.1. Month 18: FTC
ND, TFV 41.3.
Month 0: UD. Month 12: UD. Detectable TFV and FTC,
starting at randomization,
indicates drug could not
come from study partner.
Undisclosed ART at
enrollment
4 3 Female 36 TDF/FTC Month 0: FTC ND, TFV 68.6.
Month 6: FTC ND, TFV
75.2.
Month 0: UD. Month 12: UD. Detectable TFV only and no
FTC, starting at
randomization, indicates
drug could not come from
study partner. Undisclosed
ART at enrollment
5 3 Female 36 Placebo
TDF/FTC
Month 0: FTC ND, TFV ND.
Month 24: FTC ND, TFV
46.6 (Rerandomization).
Month 0: UD. Month 12: UD.
Month 24: UD.
Detectable TFV only and no
FTC, starting at re-
randomization, indicates
drug could not come from
study partner. Undisclosed
ART use during follow-up
6 3 Female 33 TDF/FTC Month 0: FTC ND; TFV ND.
Month 33: FTC ND, TFV
58.1.
Month 0: 682. Month 12: 212.
Month 24: 436.
Detectable TFV only and no
FTC indicates drug could
not come from study
partner. Undisclosed ART
use during follow-up
7 3 Female 24 TDF Month 0: FTC ND, TFV 23.8.
Month 6: FTC ND, TFV
68. Month 12: FTC ND,
TFV 52.7.
Month 0: UD. Month 12: UD. Detectable TFV, starting at
randomization, indicates
drug could not come from
study partner. Undisclosed
ART at enrollment
8 3 Female 36 TDF Month 0: FTC ND, TFV ND.
Month 6: FTC ND, TFV
ND. Month 24: FTC ND,
TFV 72.5. Month 30: FTC
ND, TFV 88.2. Month 36:
FTC ND, TFV 292.
Month 0: 1,224. Month 12:
6,086. Month 24: 650.




may be ART initiation
without reporting to the
study team
9 3 Female 33 TDF Month 0: FTC ND, TFV ND.
Month 27: FTC ND, TFV
ND. Month 30: FTC ND,
TFV ND. Month 33: FTC
ND, TFV 74.3.




may be ART initiation
without reporting to the
study team
*Plasma tenofovir .0.31 ng/mL is consistent with dosing within the last week, .10 ng/mL is consistent with dosing in the previous 2-3 days, and . 40 ng/mL is the lower bound
of the 95% confidence interval for directly observed dosing at steady state.19
†indicates plasma collected at an unannounced home visit.
ART, antiretroviral therapy; FTC, emtricitabine; TDF or TNF, tenofovir; ND, drug levels not detected (, 0.31 ng/mL); NT, not tested; UD, HIV-1 RNA viral load undetectable (,
80 copies/mL).
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3 cases of potential PrEP sharing we observed in the
current study.
Plasma was not always available at the exact same
time point for both members of the partnership because
HIV-1 uninfected participants were seen monthly and HIV-
1 infected partners were seen quarterly. It is possible that
instances of time-limited drug sharing could have been
undetected. Our study population of mutually disclosed
HIV-1 serodiscordant couples enrolled in a clinical trial
places some limitations on the generalizability of our
findings. All participants in the Partners PrEP Study
received frequent adherence counselling, including the
potential for ART drug resistance if the HIV-1 infected
study partner took study medication, counselling which is
more intensive than in an implementation setting. Never-
theless, medication sharing was feasible in our study
population.
HIV-1 serodiscordant couples have been identified as
a priority for PrEP implementation. Using prospectively
collected data, including self-report and objective testing of
drug levels in 4 groups that represent randomly selected
specimens and subpopulations with low adherence to study
medication, we comprehensively assessed PrEP sharing
within this population. Re-randomization of placebo arm
participants created a unique opportunity to assess drug
sharing when all HIV-1 uninfected partners received active
PrEP, conditions that could have incentivized drug sharing.
Importantly, we did not find an increase in drug
sharing post-unblinding.
CONCLUSIONS
Self-reported drug sharing in the Partners PrEP
Study was extremely rare. Objective plasma tenofovir
testing supports the self-reported data and indicates that
sharing PrEP within HIV-1 serodiscordant couples was
uncommon. These results suggest that it is unlikely for
medication sharing to be a serious limitation for PrEP
delivery to HIV-1 uninfected members of HIV-1
serodiscordant couples.
ACKNOWLEDGMENTS
The authors thank the couples who participated in this
study and the teams at the study sites for work on data
collection and management.
Partners PrEP Study Team.
University of Washington Coordinating Center and
Central Laboratories: Connie Celum (principal investigator,
protocol co-chair), J.M.B (medical director, protocol co-
chair), Deborah Donnell (protocol statistician), Robert W.
Coombs, Lisa Frenkel, Craig W. Hendrix, Jairam Lingappa,
M. Juliana McElrath.
Study sites and site principal investigators: Eldoret,
Kenya (Moi University, Indiana University): Kenneth Fife,
Edwin Were; Kabwohe, Uganda (Kabwohe Clinical Research
Center): Elioda Tumwesigye; Jinja, Uganda (Makerere
University, University of Washington): P.N., Elly Katabira;
Kampala, Uganda (Makerere University): Elly Katabira,
Allan Ronald; Kisumu, Kenya (Kenya Medical Research
Institute, University of California San Francisco): Elizabeth
Bukusi, Craig Cohen; Mbale, Uganda (The AIDS Support
Organization, CDC-Uganda): Jonathan Wangisi, James
Campbell, Jordan Tappero; Nairobi, Kenya (University of
Nairobi, University of Washington): James Kiarie, Carey
Farquhar, Grace John-Stewart; Kenya Medical Research
Institute, Nairobi, Kenya: Nelly Rwamba Mugo; Tororo,
Uganda (CDC-Uganda, The AIDS Support Organization):
James Campbell, Jordan Tappero, Jonathan Wangisi.
Data management was provided by DF/Net Research,
Inc. (Seattle, USA) and site laboratory oversight was
provided by Contract Laboratory Services (University of the
Witwatersrand, Johannesburg, South Africa). Study medica-
tion donated by Gilead Sciences, Inc.
REFERENCES
1. World Health Organization (WHO). Guidance on Oral Pre-Exposure
Prophylaxis (PrEP) for Serodiscordant Couples, Men and Transgender
Women Who Have Sex with Men at High Risk of HIV: Recommendations
for Use in the Context of Demonstration Projects. Geneva: World Health
Organization; 2012.
2. McCormack S, Dunn DT, Desai M, et al. Pre-exposure prophylaxis to
prevent the acquisition of HIV-1 infection (PROUD): effectiveness
results from the pilot phase of a pragmatic open-label randomised trial.
Lancet. 2016;387:53–60.
3. Marcus JL, Volk JE, Pinder J, et al. Successful implementation of HIV
preexposure prophylaxis: lessons learned from three clinical settings.
Curr HIV/AIDS Rep. 2016;13:116–124.
4. Liu AY, Cohen SE, Vittinghoff E, et al. Preexposure prophylaxis for HIV
infection integrated with municipal- and community-based sexual Health
Services. JAMA Intern Med. 2016;176:75–84.
5. Grant RM, Anderson PL, McMahan V, et al. Uptake of pre-exposure
prophylaxis, sexual practices, and HIV incidence in men and transgender
women who have sex with men: a cohort study. Lancet Infect Dis. 2014;
14:820–829.
6. Baeten JM, Heffron R, Kidoguchi L, et al. Integrated delivery of
antiretroviral treatment and pre-exposure prophylaxis to HIV-1-
serodiscordant couples: a prospective implementation study in Kenya
and Uganda. PLoS Med. 2016;13:e1002099.
7. Grelotti DJ, Closson EF, Mimiaga MJ. Pretreatment antiretroviral
exposure from recreational use. Lancet Infect Dis. 2013;13:10–12.
8. Surratt HL, Kurtz SP, Cicero TJ, et al. Antiretroviral medication
diversion among HIV-positive substance abusers in South Florida. Am
J Public Health. 2013;103:1026–1028.
9. Kurtz SP, Buttram ME, Surratt HL. Vulnerable infected populations and
street markets for ARVs: potential implications for PrEP rollout in the
USA. AIDS Care. 2014;26:411–415.
10. World Health Organization (WHO). Consolidated Guidelines on the Use
of Antiretroviral Drugs for Treating and Preventing HIV Infection.
Geneva: World Health Organization; 2013.
11. Katzenstein DA, Hammer SM, Hughes MD, et al. The relation of
virologic and immunologic markers to clinical outcomes after nucleoside
therapy in HIV-infected adults with 200 to 500 CD4 cells per cubic
millimeter. AIDS Clinical Trials Group Study 175 Virology Study Team.
N Engl J Med. 1996;335:1091–1098.
12. Baeten JM, Donnell D, Mugo NR, et al. Single-agent tenofovir versus
combination emtricitabine plus tenofovir for pre-exposure prophylaxis
for HIV-1 acquisition: an update of data from a randomised, double-
blind, phase 3 trial. Lancet Infect Dis. 2014;14:1055–1064.
13. Baeten JM, Donnell D, Ndase P, et al. Antiretroviral prophylaxis for HIV
prevention in heterosexual men and women. N Engl J Med. 2012;367:
399–410.
14. Ndase P, Celum C, Campbell J, et al. Successful discontinuation of the
placebo arm and provision of an effective HIV prevention product after
a positive interim efficacy result: the partners PrEP study experience. J
Acquir Immune Defic Syndr. 2014;66:206–212.
Thomson et al J Acquir Immune Defic Syndr  Volume 75, Number 2, June 1, 2017
188 | www.jaids.com Copyright © 2017 The Author(s). Published by Wolters Kluwer Health, Inc.
15. Haberer JE, Baeten JM, Campbell J, et al. Adherence to antiretroviral
prophylaxis for HIV prevention: a substudy cohort within a clinical trial
of serodiscordant couples in East Africa. PLoS Med. 2013;10:e1001511.
16. Bushman LR, Kiser JJ, Rower JE, et al. Determination of nucleoside
analog mono-, di-, and tri-phosphates in cellular matrix by solid phase
extraction and ultra-sensitive LC-MS/MS detection. J Pharm Biomed
Anal. 2011;56:390–401.
17. Hendrix CW, Andrade A, Bumpus NN, et al. Dose frequency ranging
pharmacokinetic study of tenofovir-emtricitabine after directly observed
dosing in healthy volunteers to establish adherence benchmarks (HPTN
066). AIDS Res Hum Retroviruses. 2016;32:32–43.
18. Musinguzi N, Muwonge T, Thomas K, et al. Does adherence change
when No one is Looking? Comparing announced and unannounced
tenofovir levels in a PrEP trial. AIDS Behav. 2016;20:2639–2643.
19. Donnell D, Baeten JM, Bumpus NN, et al. HIV protective efficacy
and correlates of tenofovir blood concentrations in a clinical trial of
PrEP for HIV prevention. J Acquir Immune Defic Syndr. 2014;66:
340–348.
20. Corneli AL, McKenna K, Perry B, et al. The science of being a study
participant: FEM-PrEP participants’ explanations for overreporting
adherence to the study pills and for the whereabouts of unused pills.
J Acquir Immune Defic Syndr. 2015;68:578–584.
21. Kahle EM, Kashuba A, Baeten JM, et al. Unreported antiretroviral use by
HIV-1-infected participants enrolling in a prospective research study.
J Acquir Immune Defic Syndr. 2014;65:e90–e94.
22. Fogel JM, Wang L, Parsons TL, et al. Undisclosed antiretroviral drug use
in a multinational clinical trial (HIV Prevention Trials Network 052).
J Infect Dis. 2013;208:1624–1628.
J Acquir Immune Defic Syndr  Volume 75, Number 2, June 1, 2017 PrEP Medication Sharing
Copyright © 2017 The Author(s). Published by Wolters Kluwer Health, Inc. www.jaids.com | 189
